**Characterization of a critical role for CFTR chloride channels in cardioprotection against ischemia/reperfusion injury**

Sunny Yang Xiang1,8, Linda L Ye1, Li-hui Liu1,3, Zhi-dong Ge2, John A Auchampach2, Garrett J Gross2, Dayue Darrel Duan1,6,7

1Department of Pharmacology, University of Nevada School of Medicine, Reno, NV 89557, USA; 2Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; 3Institute of Clinical Pharmacology, Central South University Xiangya School of Medicine, Changsha 410078, China

**Aim:** To further characterize the functional role of cystic fibrosis transmembrane conductance regulator (CFTR) in early and late (second window) ischemic preconditioning (IPC)- and postconditioning (POC)-mediated cardioprotection against ischemia/reperfusion (I/R) injury.

**Methods:** CFTR knockout (CFTR−/−) mice and age- and gender-matched wild-type (CFTR+/+) and heterozygous (CFTR+/−) mice were used. In vivo studies, the animals were subjected to a 30-min coronary occlusion followed by a 40-min reperfusion. In ex vivo (isolate heart) studies, a 45-min global ischemia was applied. To evaluate apoptosis, the level of activated caspase 3 and TdT-mediated dUTP-X nick end labeling (TUNEL) were examined.

**Results:** In the in vivo I/R models, early IPC significantly reduced the myocardial infarct size in wild-type (CFTR+/+) (from 40.4%±5.3% to 10.4%±2.0%, n=8, P<0.001) and heterozygous (CFTR+/−) littermates (from 39.4%±2.4% to 15.4%±5.1%, n=6, P<0.001) but failed to protect CFTR knockout (CFTR−/−) mice from I/R induced myocardial infarction (46.9%±6.2% vs 55.5%±7.8%, n=6, P>0.5). Similar results were observed in the in vivo late IPC experiments. Furthermore, in both in vivo and ex vivo I/R models, POC significantly reduced myocardial infarction in wild-type mice, but not in CFTR knockout mice. In ex vivo I/R models, targeted inactivation of CFTR gene abolished the protective effects of IPC against I/R-induced apoptosis.

**Conclusion:** These results provide compelling evidence for a critical role for CFTR Cl− channels in IPC- and POC-mediated cardioprotection against I/R-induced myocardial injury.

**Keywords:** ischemia; preconditioning; postconditioning; apoptosis; cystic fibrosis transmembrane conductance regulator (CFTR)

**Introduction**

Ischemia and reperfusion (I/R) induce myocardial injury and lead to infarction through increased apoptosis (programmed cell death) and necrosis[8-10]. Ischemic preconditioning (IPC) is a phenomenon in which brief episodes of ischemia dramatically reduce myocardial infarct size produced by a subsequent sustained ischemia and reperfusion[11]. IPC has an early phase (lasting 1-2 h) and a late phase or “second window” (lasting 24-72 h) of protection[12]. The signaling pathways involved in both early IPC (EIPC) and late IPC (LIPC) have been the subject of numerous intensive studies ever since IPC was first described by Murry et al in 1986[13,14]. The end-effectors of these signaling pathways are believed to directly participate in protecting the myocardium from subsequent ischemia/reperfusion insults after IPC[15,16]. Both sarcolemmal and mitochondrial ATP-sensitive potassium channels (sarc-K_{ATP} and mito-K_{ATP}, respectively) have been suggested to serve as mediators or end-effectors in EIPC and LIPC[17,18]. Many other factors have also been proposed to be end-effectors, including the mitochondrial permeability transition pore (mPTP)[19], the sodium/hydrogen exchanger[20], and swelling-activated Cl− channels[21,22]. Although it has been shown that specific blockades of each proposed end-effector completely abolish the protection given by IPC, the identification of which factors are true end-effectors and the elucidation of possible interactions between these end-effectors have yet to be established[23,24,25].
In 2003, Zhao et al. reported that short episodes of I/R immediately after sustained ischemia and before full reperfusion reduced myocardial infarct size to a level equivalent to IPC in dogs. This phenomenon was named ischemic postconditioning (POC)\(^{[28]}\). POC is as powerful as EIPC and LIPC in reducing myocardial infarction and preserving functional performance of the heart and also has the potential to be clinically applicable in the most common situations of unexpected coronary occlusion and acute myocardial infarction\(^{[16–18]}\). To date, POC has been documented in dog, pig, rabbit, rat, and mouse models and in humans\(^{[6, 16, 19–22]}\). This widespread occurrence of POC has aroused a renewed interest in understanding the mechanisms of cell death during I/R and identifying endogenous mediators of cardioprotection against I/R injury\(^{[6, 17, 18, 22, 23]}\). Many studies suggest that POC shares some signaling pathways with IPC, including activation of PKC, PKA, PI3K-Akt, and the MEK1/2-Erk1/2 pathways. Both mito-K\(_{\text{ATP}}\) and mPTP are also thought to be key players or potential end-effectors in POC\(^{[24, 25]}\).

A recent study in isolated mouse hearts supports a potential role for the cystic fibrosis transmembrane-conductance regulator (CFTR) in acute IPC\(^{[26]}\). The CFTR gene belongs to the ATP-binding cassette (ABC) transporter superfamily and encodes a PKC- and PKA-activated Cl\(^{-}\) channel in the heart\(^{[27–29]}\). The sulfonyleurea receptor (SUR) and mABC1 are also included in the same ABC superfamily. SUR combines with inward rectifier K\(^{+}\) (Kir6.1, Kir6.2) channel subunits to form functional sarc-K\(_{\text{ATP}}\) channels\(^{[8, 9]}\), and mABC1 was suggested to be a component of mito-K\(_{\text{ATP}}\)\(^{[31]}\). While both sarc-K\(_{\text{ATP}}\) and mito-K\(_{\text{ATP}}\) channels have been extensively studied for their roles as important mediators of IPC and POC, the relative functional role of cardiac CFTR channels in EIPC, LIPC, and POC has not been studied. This study was designed to directly address this question with CFTR-knockout (CFTR\(^{-/-}\)) mice and age- and gender-matched wild-type (WT, CFTR\(^{+/+}\)) and heterozygous (CFTR\(^{+/−}\)) mice.

**Materials and methods**

This investigation conforms to the Guide for the Care and Use of Laboratory Animals (US National Institute of Health publication No 85–23, revised 1996) and was carried out in accordance with the Institutional Guidelines for Animal Care and Use approved by the University of Nevada Institutional Animal Care and Use Committee.

**Breeding and genotyping of transgenic mice**

STOCKCftrtm1Unc-TgN (FABPCFTR)Jaw breeders obtained from Dr Jeffrey Whitsett (Children’s Hospital Medical Center, Cincinnati, OH, USA) were bred in our transgenic animal facility as previously described\(^{[26]}\). Eight- to twelve-week-old male CFTR\(^{-/-}\) offspring and age- and gender-matched CFTR\(^{+/+}\) and CFTR\(^{+/−}\) littermates were used. These mice were genotyped by performing polymerase chain reaction (PCR) on genomic DNA isolated from tail samples using a three-primer assay (5’-GAG AAC TGG AAG CTT CAG AGG-3’, 5’-TCC ATC TTG TTC AAT GGC C-3’, and 5’-TCC ATG TAG TGG TGT GAA CG-3’), which resulted in a 357-bp band for CFTR\(^{-/-}\), a 526-bp band for CFTR\(^{+/+}\), and both bands for CFTR\(^{+/−}\).

**In vivo I/R injury**

Mice were anesthetized with sodium pentobarbital (50 mg/kg, ip), placed on a 37 °C heated pad, intubated, and ventilated using a mouse ventilator (Harvard Apparatus, Germany) with air (respiration frequency 120 strokes/min). Body temperature was maintained at about 37 °C with the heating pad. Surface 12-lead ECG was recorded throughout the experiments on a Gould ACQ-7700 recorder (Gould Instrument Systems, Valley View, OH, USA). A left thoracotomy was performed, and the left anterior descending (LAD) coronary artery 2–3 mm from the tip of the left atrium was occluded with an Ethicon 8.0-silk suture (ETHICON, INC). Successful coronary occlusion was verified by the development of a pale color in the distal myocardium, which was observed using a Surgical Microscope system (Applied Fiberoptics, Southbridge, Massachusetts), and by S–T segment elevation and QRS widening on the ECG. Blood flow was restored by releasing the ligate. Successful reperfusion was confirmed when the bright red color of the left ventricle (LV) and the ECG returned to normal. A 30-min coronary occlusion (ischemia) was used in the in vivo studies. Either a 40-min or a 24-h reperfusion period was used according to different protocols.

**In vivo EIPC, LIPC, and POC**

To simulate EIPC, 3 I/R cycles of 4 min each were applied immediately before a sustained 30-min ischemia followed by a 40-min reperfusion, after which the chest was closed. Mice were allowed to recover for 24 h before their hearts were removed to measure infarct size. To simulate LIPC, 3 brief (4 min) I/R cycles (IPC) were applied on d 1, and a sustained ischemia (30 min) and reperfusion (40 min or 24 h) injury was created on d 2, while in the I/R controls, no IPC intervention was used on d 1. To simulate POC, 6 brief cycles (10 s) of LAD reflow/reocclusion were applied during the first minute of reperfusion immediately following a 30-min LAD coronary artery occlusion, while the control group received no interventions during reperfusion.

**Ex vivo IPC and POC models (isolated Langendorff and working heart preparations)**

The aorta and left atrium were cannulated and connected to the HSE isolated heart perfusion system (model IH-1, Harvard Apparatus, Inc) immediately after removal from mice to allow measurements to be obtained in the working-heart mode (afterload=60 mmHg, preload=10 mmHg) as described previously\(^{[26]}\). Left ventricular pressure (LVP), LV developed pressure (LVDP), and LV end-diastolic pressure (LVEDP) were measured with a Millar tip catheter (1.4/0.8F pressure transducer, Millar) inserted into the LV cavity through the aorta. Measurements of functional performance, including aortic pressure (AP), heart rate (HR), left ventricular pressure (LVP), LV developed pressure (LVDP), first derivative of maximum and minimum LVDP (±dP/dt), and LV end-diastolic pressure...
(LVEDP) were recorded continuously during the experiment and analyzed offline by an HSE data acquisition system (HSE Haemodyn, Harvard Apparatus). Total global ischemia, which was produced by clamping both atrial inflow and aortic outflow, was used to induce sustained ischemia and IPC and POC interventions. Myocardial infarct size was determined using 2,3,5-triphenyltetrazolium chloride (TTC) staining as described previously[26].

Measurement of infarct size
At the end of each protocol, the heart was stained with 0.1 mL 5% Phthalo Blue (Heucotech LTD, USA) and 1 mL of 1% TTC and then removed. The area at risk and the infarct size of the left ventricle were quantified by a blinded observer using the image processing and analysis (IPA) module of Simple PCI image analysis software (Compic, Inc, USA)[26]. The percent infarction was calculated for each slice and reported as the percent of infarct tissue divided by the total area at risk.

Active caspase 3 assay
Hearts from CFTR+/+ or CFTR−/− mice were subjected to 45 min of ischemia and 180 min of reperfusion in the isolated Langendorff and working heart system to create I/R injury. Three brief 5-min cycles of I/R applied immediately before a sustained ischemic event were used for the IPC intervention. Control hearts were subjected to a 240-min perfusion to evaluate baseline activated caspase 3 activity. At the end of the experiments, the hearts were snap frozen in liquid nitrogen and stored at -80 °C. The hearts were then pulverized and homogenized in RIPA buffer in the presence of a protease inhibitor cocktail (Sigma, Saint Louis, MO, USA, P8340) with a Kontes-Duall glass homogenizer. The homogenates were incubated on ice for 30 min and centrifuged in a microcentrifuge at maximal speed (about 14000 r/min) for 10 min at 4 °C. The supernatant (whole lysate) was collected, and protein concentrations were determined using the BCA protein assay. The supernatants were then incubated with SDS loading buffer at 95 °C for 5 min, separated by 12% SDS-PAGE, and transferred to a nitrocellulose (NC) membrane for immunoblot analysis. Following SDS-PAGE, the NC membrane was blocked with Odyssey blocking buffer (Li-COR, Lincoln, NA, USA, 927-4000) for 45 min and incubated with primary rabbit polyclonal anti-active caspase 3 antibody (1 µg/mL, Abcam, ab2302) overnight at 4 °C with rocking. To detect active caspase 3, the membrane was then incubated with Alexa Fluor 680 goat anti-rabbit secondary antibody (dilution 1:5000, #A21076, Invitrogen, Carlsbad, CA, USA) for 45 min at room temperature, and the membranes were washed and then scanned with the Odyssey infrared imaging system at 700 nm and processed with Odyssey software (V1.2, Li-COR). GAPDH was used as an internal control.

TUNEL assay
To identify apoptotic cells containing DNA fragments, tissue samples (serial 8 µm cryosections) were immunohistochemically stained using terminal deoxynucleotidyl transferase (TdT) and fluorescein conjugated nucleotides with the in situ cell death detection kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer’s instructions. Negative control sections were prepared without the TdT enzyme. Labeled nuclei were identified from the negative nuclei counterstained by propidium iodide (PI) (Vector Laboratories, Inc Burlingame, CA, USA) and counted after being photographed under a fluorescence microscope at 40×magnification. The percentage of TUNEL-positive nuclei (cell) was calculated as the number of TUNEL-labeled nuclei (green)/total nuclei (PI-labeled, red).

Statistical analysis
All group data are presented as the mean±SEM. ANOVA and Student’s t test were used to determine statistical significance. A 2-tailed probability value of P<0.05 was considered statistically significant.

Results
Functional role of CFTR in EIPC-mediated cardioprotection
Age-matched male CFTR+/+, CFTR+/−, and CFTR−/− mice were randomly divided into I/R (control) and EIPC groups following the experimental protocols depicted in Figure 1A. In the control group, mice were subjected to 24 min of open-chest exposure (sham) followed by a sustained 30-min occlusion and a 40-min reperfusion. In the EIPC group, 3 I/R cycles of 4 min each were applied immediately before a sustained 30-min ischemia followed by a 40-min reperfusion, and then the chest was closed. The mice were allowed to recover for 24 h before the hearts were removed to measure infarct size. Representative images of Phthalo Blue and TTC stained LV sections from each group are shown in Figure 1B. As seen in Figure 1C, EIPC significantly reduced the size of the infaracts caused by 30-min sustained ischemia and 24-h reperfusion (expressed as a percentage of the risk region) in the CFTR+/+ (from 40.4%±5.3% to 10.4%±2.0%, n=8, P<0.001) and CFTR+/− mice (from 39.4%±2.4% to 15.4%±5.1%, n=6, P<0.001). However, EIPC failed to protect the hearts of CFTR−/− mice (46.9%±6.2% in I/R control vs 55.5±7.8% in EIPC, n=6, P>0.5). These results suggest that CFTR Cl− channels are involved in the cardioprotective effects of EIPC in vivo.

Functional role of CFTR in LIPC-mediated cardioprotection
To test whether CFTR is involved in LIPC cardioprotection in vivo, age-matched male CFTR+/+, CFTR+/−, and CFTR−/− mice were randomly divided into four groups following the experimental protocols depicted in Figure 2A. In the LIPC group, 3 brief (4 min) I/R cycles (IPC) were applied on d 1, and a sustained ischemia (30 min) and reperfusion (40 min or 24-h) injury was created on d 2, while in the I/R controls, no IPC intervention was used on d 1. The reason both a 40-min and a 24-h reperfusion were used in the LIPC protocols was to compare LIPC with EIPC and also to examine long term protection provided by LIPC. Similar to what was seen with EIPC, LIPC significantly reduced the size of the infarcts caused by sustained I/R injury in both CFTR+/+ (from 44.9%±5.1%
to 20.6±2.6%, n=7, P<0.001 in the groups with 40-min reperfusion and from 39.6±4.1% to 18.3±1.8% in the groups with 24-h reperfusion) and CFTR+/− mice (from 39.9±4.1% to 19.4±1.7%, n=6, P<0.001 in the groups with 40-min reperfusion, and from 40.2±3.2% to 21.6±2.0%, n=5, P<0.001 in the groups subjected to 24-h reperfusion).

However, LIPC failed to provide protection against I/R injury in hearts from CFTR –/– mice (42.6%±4.1% in control vs 40.8%±5.3% in LIPC with 40-min reperfusion, n=7, P>0.05, and 36.8%±3.2% in control vs 39.8%±4.7% in LIPC with 24-h reperfusion, n=5, P>0.05), as shown in Figures 2B and 2C. These results strongly indicate that CFTR may play a very important role in LIPC-mediated cardioprotection in the mouse heart.

Functional role of CFTR in POC-mediated cardioprotection

To examine whether CFTR Cl− channels play a role in POC, we first established an ex vivo model of POC. Isolated Langendorff (retrograde) and working-heart (antegrade) perfusion preparations[26] from CFTR–/– and CFTR+/+ mice were subjected to the experimental protocols shown in Figure 3A. Functional and histological changes to the hearts during I/R and POC were studied. A 45-min period of ischemia was applied as the index ischemia. Six cycles of 10-s ischemia/reperfusion initiated in the first minute of reperfusion following the index ischemia were used as the POC intervention. I/R groups received no interventions during reperfusion. As shown in Table 1, I/R injury caused a significant decrease in heart function as evaluated by HR, LVDP, and ±dp/dt in both CFTR+/+ and CFTR–/– mice; however, in hearts subjected to POC, post-ischemic cardiac function was restored to levels close to the baseline seen before the ischemic event in CFTR+/+ but not CFTR–/– mice.

The infarct size was also measured to assess myocardial tissue injury and viability, and representative images of stained LV sections from each group are shown in Figure 3B. The size of infarcts caused by 45-min ischemia was significantly reduced from 37.5%±3.4% to 17%±2.0% (P<0.005, n=4) by POC in the hearts of CFTR+/+ mice but not CFTR–/– mice (control, 40.4%±4.1% vs POC 45%±7.7%, P>0.1, n=5). These results strongly suggest that targeted inactivation of the CFTR gene in

Table 1. Effects of CFTR gene knockout on POC-induced changes in hemodynamics of the isolated perfused mouse heart. *P<0.05, †P<0.01, 40-min R vs baseline. Data are represented as mean±SEM.

| CFTR+/+ | CFTR–/– |
|-----------------|-----------------|
| **Baseline** | **I/R** | **POC** | **Baseline** | **I/R** | **POC** |
| Heart rate (bpm) | 387±29 | 312±14* | 397±10 | 379±15 | 378±20 | 295±5* |
| LVDP (mmHg) | 100.5±2.2 | 61.6±5.6* | 103.9±4.0 | 89.7±49 | 113.9±8.4 | 66.1±6.9* |
| +dp/dt (mmHg/s) | 7313±290 | 2874±125* | 8215±298 | 6451±476* | 8689±101 | 3088±234* |
| -dp/dt (mmHg/s) | 5792±327 | 2618±177* | 5908±323 | 4707±483 | 6256±899 | 2233±104* |

I/R: ischemia/reperfusion; LVDP: left ventricular developed pressure; +dp/dt: maximum rate of change in LVDP; -dp/dt: minimum rate of change in LVDP. Hemodynamic parameters at baseline were measured at the end of the 10 min of working heart perfusion before ischemia/reperfusion protocol. Results measured at the end of 40 min of reperfusion (40-min R) after 45 min of global ischemia without postconditioning (I/R) or with postconditioning (POC) were compared with those measured at baseline.
the mouse abolishes the cardioprotective effect of POC against sustained I/R in isolated hearts.

A “gold standard” for confirmation of the potential role of CFTR Cl– channels in POC protection is to test whether POC also protects the heart from in vivo I/R injury. Therefore, an in vivo model of POC was established in CFTR<sup>−/−</sup> mice and their CFTR<sup>+/−</sup> littermates to test the effects of targeted inactivation of the CFTR gene on in vivo POC protection in mice.

Open-heart surgery was performed on male CFTR<sup>−/−</sup> mice (8–12 week-old) and age-matched CFTR<sup>+/+</sup> and CFTR<sup>+/−</sup> littermates, and coronary artery occlusion and POC protocols were performed (Figure 4A). Immediately following a 30-min LAD coronary artery occlusion, which was applied as the index ischemia to induce about 40% infarct size in the hearts of mice in the control group, 6 brief cycles (10 s) of LAD reflow/reocclusion were applied in the first minute of reperfusion, while the control group received no interventions during reperfusion. At the end of each experimental protocol, the hearts

---

**Figure 2.** Effect of CFTR knockout on late (second window) preconditioning (LIPC). (A) Experimental protocols. Protocol for each group is applied to CFTR<sup>−/−</sup> mice and age-matched WT and CFTR<sup>+/−</sup> littermates. (B) Mean infarct size in Group 1 (I/R) & 2 (IPC) with 40-min reperfusion. (C) Mean infarct size in Group 3 (I/R) & 4 (IPC) with 24 hr reperfusion.

---

**Figure 3.** Effects of CFTR knockout on postconditioning (POC) in isolated hearts. (A) Experimental protocols. Protocol for each group is applied to CFTR<sup>−/−</sup> mice and age-matched WT littermates. W: working, P: perfusion, R: reperfusion. (B) Representative staining of ventricle transverse slices after ischemia/reperfusion (I/R) or postconditioning (POC). (C) Individual infarct size measured from each age- and gender-matched WT and CFTR<sup>−/−</sup> mouse hearts after control or POC, mean value with error bar (mean±SEM) were also shown for each group.
were stained by TTC and Phthalo Blue (Figure 4B) and the infarct size (% of the region at risk) was calculated. As seen in Figure 4C, a 30-min ischemia/24-h reperfusion caused an infarct size of 46.1%±8.3% (n=4) in CFTR+/+ mice and an infarct size of 46.3%±8.3% (n=5) in CFTR−/− mice. POC significantly reduced the infarct size within the risk zone to 14.4%±2.4% (n=4, P<0.05) in the CFTR+/+ mice but not in the CFTR−/− mice (40.8%±1.2%, n=5, P>0.5). These results further confirm an important role of CFTR in POC-mediated cardioprotection against I/R injury in mouse hearts.

**Effect of targeted inactivation of the CFTR gene on apoptosis**

It has been demonstrated previously that apoptosis and necrosis are the major cell death pathways involved in I/R injury and myocardial infarction and that both IPC and POC can reduce I/R-induced apoptosis[1, 2, 32, 33]. To test whether activation of CFTR Cl− channels is important in IPC-mediated inhibition of apoptosis, isolated Langendorff and working heart preparations from ex vivo IPC models from age-matched male CFTR+/+ and CFTR−/− mice were examined. As shown in Figure 5, post-ischemic functional performance, as estimated by LVDP, +dp/dt, and -dp/dt, was significantly improved by IPC in CFTR+/+ mouse hearts compared to non-preconditioned CFTR+/+ mouse hearts but not in CFTR−/− mouse hearts (Figure 5B-5D). A separate group of control hearts was subjected to normal perfusions without I/R to investigate the amount of apoptosis that develops during I/R using the isolated heart perfusion system. Our results showed that a 240-min perfusion resulted in little caspase 3 activation (control) but that sustained I/R caused a significant increase in caspase 3 activation in both CFTR+/+ and CFTR−/− mouse hearts. I/R induced caspase 3 activation, however, was significantly reduced by IPC in hearts of CFTR+/+ mice to a level similar to that of CFTR−/− control mice. In hearts of CFTR−/− mice, the level of active caspase 3 was not reduced by IPC, indicating loss of IPC-induced inhibition of apoptosis in these hearts (Figure 5A and 5B).

To confirm our observations on the effects of knocking out CFTR on apoptosis of cardiac myocytes, TUNEL assays were performed to detect apoptotic cells under I/R and IPC conditions. Figure 5C shows a representative image of TUNEL assays in mouse heart sections. In these studies, the reperfusion time was increased to >360 min to allow DNA damage to develop. In control hearts not subjected to global I/R, 420 min of perfusion led to the appearance of some TUNEL-positive (TN-P) nuclei in the epicardium, but no TN-P nuclei were detected in the deeper layers of the myocardium (data not shown). I/R resulted in the appearance of 26.1%±2.15% and 29.28%±4.98% TN-P nuclei in hearts of CFTR+/+ and CFTR−/− mice, respectively. IPC significantly reduced TN-P nuclei in hearts of CFTR+/+ mice (3.77±0.28, P<0.001) but not hearts of CFTR−/− mice (24.79%±3.17%, P>0.1) (Figure 5D). These results suggest that CFTR is very important for IPC-mediated inhibition of apoptosis in the heart.

**Discussion**

Although our previous study in isolated heart preparations suggested a potential role of CFTR in acute IPC, it is not clear what the exact function of CFTR is in in vivo EIPC and IPC or whether CFTR is involved in POC[26-28]. In this study, therefore, we investigated the relative role of CFTR Cl− channels in in vivo EIPC and IPC in the mouse heart. Our results demonstrate that CFTR Cl− channels are important for both EIPC- and LIPC-mediated cardioprotection. In addition, our results provide strong evidence for a novel and critical role for CFTR Cl− channels in POC-mediated cardioprotection. Furthermore, we found that CFTR may exert its cardioprotective effects through inhibition of apoptosis.

**Functional role of Cl− channels in IPC-mediated cardioprotection**

For historical reasons, the potential role of Cl− channels in cardiac physiology has been ignored[27, 28]. The first evidence for
the potential involvement of Cl⁻ channels in IPC came from a study by Diaz et al., which demonstrated that the Cl⁻ channel blockers 5-nitro-2-(3-phenylpropyl-amino) benzoic acid (NPPB) and indanyloxyacetic acid 94 (IAA-94) not only block hypo-osmotic cell swelling induced by Cl⁻ current (\( I_{\text{Cl, swell}} \)) but also prevent IPC- and hypo-osmotic stress-mediated protection of isolated rabbit hearts\(^{[13]}\). Subsequent studies from the same group provided further evidence supporting the notion that \( I_{\text{Cl, swell}} \) may be an important end-effector in IPC\(^{[34, 35]}\), and it is believed that enhanced cell volume regulation may be a key mechanism for IPC protection\(^{[12]}\). These observations by Diaz et al. were, however, seriously questioned by Heusch et al.\(^{[36, 37]}\).

In an attempt to confirm the effects of the same Cl⁻ channel blockers on both Cl⁻ channel activity in isolated ventricular myocytes and cardioprotection by IPC in isolated perfused rabbit heart, Heusch et al. found that the channel-blocking concentrations of both NPPB and IAA-94 were toxic in isolated perfused rabbit hearts, as evidenced by cessation of cardiac contraction and massive infarction. Thus, neither agent could be used to test the role of Cl⁻ channels on the anti-infarct effect of IPC. The doses used in the report by Diaz et al.\(^{[13]}\) did not affect coronary flow, heart rate, or developed pressure and also failed to prevent infarct size reduction by IPC\(^{[36]}\). Similar results were obtained with another VSOACs blocker, 4,4'-

---

**Figure 5.** Effects of targeted inactivation of CFTR gene on apoptosis during I/R or IPC. (A) Western blots (WB) analysis of activated caspase 3 in an isolated perfusion heart model for either WT or CFTR\(^{-/-}\) mice exposed to reperfusion alone (control), ischemia/reperfusion (I/R) or ischemic preconditioning (IPC) protocols. After control (5 h perfusion), I/R (45 min ischemia/3 h reperfusion) or IPC (3 cycles of 5 min I/R right before the 45 min ischemia/3 h reperfusion) treatments, hearts lysates from each group were obtained and subjected to WB analysis for activated caspase 3. GAPDH was immunoblotted as a loading control. (B) Relative active caspase-3 density after normalized to GAPDH. (C) Representative images of heart longitudinal sections of TUNEL staining for each group of treatments: I/R (45 min ischemia/6 h reperfusion) or IPC (3 cycles of 5 min I/R right before the 45 min ischemia/6 h reperfusion). Green: TUNEL stained nuclei; red, propidium iodide (PI) stained nuclei. (D) Relative percentage of TUNEL positive (TP) cells calculated as 100% * (count of TP/count of PI), data presented as mean±SEM (error bar), *\( n=6 \), \( *P=0.0027 \).
The difficulty in resolving these controversies stems from the fact that multiple types of Cl– channels (CFTR, I_{Cl,swell} etc) are concomitantly expressed in the same cardiac cell[27, 28] and the Cl– channel blockers used in these studies lack specificity towards any particular subgroup of Cl– channels in the heart[13, 35, 36]. Therefore, the use of a gene targeting technique to specifically inactivate Cl– channel (eg, CFTR) gene expression in the mouse provides a unique and powerful approach to directly address the question of whether Cl– channels play a role in the early and late phases of IPC.

**Relationship between CFTR and sarc-KATP channels**

CFTR belongs to the ABC transport superfamily[38] and shares similar structural features, including transmembrane and nucleotide binding domains, with SUR, a subunit of functional sarc-KATP channels[39]. However, CFTR is the only member of the ABC family that encodes a protein with a transport structure and Cl– channel function[38]. CFTR is unique in forming an anion channel gated by PKA and PKC phosphorylation and intracellular ATP[29, 30]. Interestingly, sulfonureas such as glibenclamide, which have long been used as specific blockers of sarc-KATP channels in IPC studies[8, 9], can also block CFTR Cl– channels[40, 41]. However, a potential role for CFTR Cl– channels as endogenous protective factors in IPC and POC has been ignored. In this study, we provide the first compelling experimental evidence for a novel and critical functional role of CFTR channels in IPC and POC-mediated cardioprotection. Therefore, CFTR may represent a novel target for cardioprotection against I/R injury.

**Mechanisms of activation of CFTR in IPC- and POC-mediated cardioprotection against I/R injury**

CFTR Cl– channels are expressed in many species ranging from mice to humans[29]. It is well established that cardiac CFTR channels can be activated by PKA and PKC through a vast array of signaling pathways such as activation of β-adrenergic receptors[30] and purinergic receptors[42]. It is thus conceivable that cardiac CFTR channels can be activated by signaling mechanisms invoked during IPC and POC, including PKCε activation via G-protein (possibly Gq and/or Gi)-coupled receptors[37, 38].

Apoptosis and necrosis are the major cell death mechanisms involved in ischemia- and reperfusion-induced myocardial injury and infarction[1, 2]. Considerable evidence has demonstrated that activation of CFTR channels may be an important modulator of apoptotic mechanism in non-cardiac cells[43–45]. For example, glibenclamide, an inhibitor of CFTR Cl– channels[40, 41] that has been mistaken as a specific blocker of sarc-KATP channels[8, 9], induces apoptosis in a dose- and time-dependent manner in HepG2 human hepatoblastoma cells[43]. In this study, we found that targeted inactivation of CFTR abolished the protective effects of IPC on I/R-induced apoptosis, suggesting that CFTR channels may be involved in IPC- and POC-mediated cardioprotection through inhibition of apoptosis. It has been suggested that the anti-apoptotic effect of CFTR may be a result of strengthened cell volume homeostasis during cell proliferation and apoptosis[46]. Other mechanisms behind CFTR-mediated effects on apoptosis may involve the role of CFTR in the regulation of intracellular reactive oxygen species (ROS) and glutathione content (GSH/GSSG)[47]. It should be pointed out, however, that in several other cell types, activation of CFTR has been reported to actually enhance apoptosis[47–49]. The reason for the multifaceted role of CFTR in apoptosis is not currently known[50]. However, Yalcin et al recently found that the majority of apoptotic cells in CF patients are alveolar epithelial cells, and apoptotic cells are not detected in other locations where CFTR expression is much more prominent than alveolar cells. They postulated, therefore, that increased apoptosis in the alveolar epithelium is related to the presence of chronic infections rather than CFTR dysfunction[51].

In addition, activation of CFTR Cl– channels may protect the heart against arrhythmogenesis by preventing excessive prolongation of action potential duration (APD) and protecting the heart against the development of early after depolarizations (EAD) and triggered activity caused by activation of Ca2+ channels in the presence of β-adrenergic stimulation[28, 29]. It has been demonstrated that cardiac CFTR plays a role in early action potential shortening during hypoxia and ischemia[52]. Activation of CFTR also decreases resting membrane potential and action potential duration, thereby limiting intracellular Ca2+ overload and cell damage[29]. These beneficial effects of the activation of cardiac CFTR may serve as mechanisms behind the cardioprotection of CFTR against I/R injury during IPC or POC.

Numerous previous studies have demonstrated that CFTR is not only a Cl– channel but also a transporter for many other molecules such as sphingosine-1-phosphate[53], an important lipid messenger involved in IPC[54]. CFTR may interact with many proteins that either directly or indirectly impact the function of other ion channels and transporters, such as epithelial Na+ channels (ENaC) and Ca2+- and volume-activated Cl– channels[50]. Evidence is emerging that CFTR assembles into large, dynamic macromolecular complexes that contain signaling molecules, kinases, transport proteins, PDZ-domain-containing proteins, myosin motors, and Rab GTPases[56]. Therefore, CFTR may be involved in the regulation of a variety of cellular functions. The integrated versatile function and complex regulation of CFTR channels may be orchestrated by many proteins in the CFTR interactome[57]. It is thus very important to further study the underlying molecular mechanisms behind CFTR-mediated cardioprotection and the interplay between CFTR and other cardioprotective factors such as sarc-KATP, mito-KATP, and mPTP. Such studies may shed new light on the functional role of CFTR Cl– channels in the heart and increase our understanding of the complicated mechanisms behind endogenous cardioprotection.
**Acknowledgements**

We are grateful to Dr William HATTON and Dr Hong-lin TIAN for their excellent technical assistance. This study was supported by the National Center for Research Resources P-20 RR-15581 (Dayue Darrel DUAN); National Heart, Lung, and Blood Institute Grants HL106256 and HL63914 (Dayue Darrel DUAN), HL60051 (John A AUCHAMPACH), HL 077707 (John A AUCHAMPACH), and HL 08311 (Garrett J GROSS); American Diabetes Association Innovation Award #07-8-IN-08 (Dayue Darrel DUAN); and the National Basic Research Program of China Grant 2009CB521903 (Dayue Darrel DUAN).

**References**

1. Lopez-Neblina F, Toledo AH, Toledo-Pereyra LH. Molecular biology of apoptosis in ischemia and reperfusion. J Invest Surg 2005; 18: 335–50.
2. Zhao QZ, Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc Res 2002; 55: 438–55.
3. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1142–36.
4. Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, Bolli R. Demonstration of an early and late phase of ischemic preconditioning in mice. Am J Physiol 1998; 275: H1375–87.
5. Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech 2010; 3: 35–8.
6. Ovize M, Baxter GF, Di LF, Ferdinandy P, Garcia-Dorado D, Hausenloy D, et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010; 87: 406–23.
7. Downey JM, Davis AM, Cohen MV. Signalling pathways in ischemic preconditioning. Heart Fail Rev 2007; 12: 181–8.
8. Gross GJ, Peart JN. KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 2003; 285: H921–30.
9. Gross GJ. Selective ATP-sensitive potassium channel openers: fact or fiction. J Mol Cell Cardiol 2003; 35: 1005–7.
10. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2006; 101: 354–56.
11. Xiao XH, Allen DG. Activity of the Na+/H+ exchanger is critical to reperfusion damage and preconditioning in the isolated rat heart. Cardiovasc Res 2000; 48: 244–53.
12. Diao RJ, Armstrong SC, Batthish M, Backx PH, Ganote CE, Wilson GJ. Enhanced cell volume regulation: a key protective mechanism of ischemic preconditioning in rabbit ventricular myocytes. J Mol Cell Cardiol 2003; 35: 45–58.
13. Diao RJ, Losito VA, Mao GD, Ford MK, Backx PH, Wilson GJ. Chloride channel inhibition blocks the protection of ischemic preconditioning and hypo-osmotic stress in rabbit ventricular myocardium. Circ Res 1999; 84: 763–75.
14. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J 2009; 73: 1171–7.
15. McIntosh VJ, Lasley RD. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J Cardiovasc Pharmacol Ther 2011 doi:10.1177/1074248410396877.
16. Zhao QZ, Corvera JS, Haloks ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic preconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285; H579–88.
17. Zhao QZ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 2006; 70: 200–11.
18. Gross GJ, Auchampach JA. Reperfusion injury: does it exist? J Mol Cell Cardiol 2007; 42: 12–8.
19. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res 2006; 70: 308–14.
20. Heusch G, Buchert A, Fedlhaus S, Schulz R. No loss of cardioprotection by postconditioning in connexin 43-deficient mice. Basic Res Cardiol 2006; 101: 354–6.
21. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, et al. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 2009; 104: 15–8.
22. Peart JN, Headrick JP. Clinical cardioprotection and the value of conditioning responses. Am J Physiol Heart Circ Physiol 2009; 296: H1705–20.
23. Heusch G. Postconditioning: old wine in a new bottle? J Am Coll Cardiol 2004; 44: 1111–2.
24. Burley DS, Baxter GF. Pharmacological targets revealed by myocardial postconditioning. Curr Opin Pharmacol 2009; 9: 177–88.
25. Granfeldt A, Lefer DJ, Vinten-Johansen J. Protective ischaemia in patients: preconditioning and postconditioning. Cardiovasc Res 2009; 83: 234–46.
26. Chen H, Liu LL, Ye LL, McGuckin C, Tamowski S, Scowen P, et al. Targeted inactivation of cystic fibrosis transmembrane conductance regulator chloride channel gene prevents ischemic preconditioning in isolated mouse heart. Circulation 2004; 110: 700–4.
27. Duan D. Phenomics of cardiac chloride channels: the systematic study of chloride channel function in the heart. J Physiol 2009; 587: 2163–77.
28. Duan D, Liu LL, Bozeat N, Huang ZM, Xiang SY, Wang GL, et al. Functional role of anion channels in cardiac diseases. Acta Pharmacol Sin 2005; 26: 265–78.
29. Hume JR, Duan D, Collier ML, Yamazaki J, Horowitz B. Anion transport in heart. Physiol Rev 2000; 80: 31–81.
30. Sheppard DN, Walsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999; 79: S23–S45.
31. Burke MA, Ardehali H. Mitochondrial ATP-binding cassette proteins. Transl Res 2007; 150: 73–80.
32. Gateau-Roesch O, Argaud L, Ovize M. Mitochondrial permeability transition pore and postconditioning. Cardiovasc Res 2006; 70: 264–73.
33. Obal D, Dettwiler S, Favoccia C, Scharbatke H, Preckel B, Schlack W. The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth Analg 2005; 101: 1252–60.
34. Batthish M, Diao RJ, Zeng HP, Backx PH, Wilson GJ. Pharmacological preconditioning in rabbit myocardium is blocked by chloride channel inhibition. Cardiovasc Res 2002; 55: 660–71.
35. Diao RJ, Batthish M, Backx PH, Wilson GJ. Chloride channel inhibition blocks the protection of ischemic preconditioning in myocardium. J Mol Cell Cardiol 2001; 33: 1887–9.
36. Heusch G, Liu GS, Rose J, Cohen MV, Downey JM. No confirmation for a causal role of volume-regulated chloride channels in ischemic preconditioning in rabbits. J Mol Cell Cardiol 2000; 32: 2279–85.
37. Heusch G, Cohen MV, Downey JM. Ischemic preconditioning through opening of swelling-activated chloride channels? Circ Res 2001; 89: E48.
38. Riordan JR, Chang X. CFTR, a channel with the structure of a transporter. Biochim Biophys Acta 1992; 1101: 221–2.
39. Nichols CG. KATP channels as molecular sensors of cellular metabo-
lism. Nature 2006; 440: 470–6.

40 Sheppard DN, Welsh MJ. Effect of ATP-sensitive K+ channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents. J Gen Physiol 1992; 100: 573–91.

41 Yamazaki J, Hume JR. Inhibitory effects of glibenclamide on cystic fibrosis transmembrane regulator, swelling-activated, and Ca2+-activated Cl– channels in mammalian cardiac myocytes. Circ Res 1997; 81: 101–9.

42 Duan D, Ye L, Britton F, Miller LJ, Yamazaki J, Horowitz B, et al. Purinoceptor-coupled Cl– channels in mouse heart: a novel, alternative pathway for CFTR regulation. J Physiol (Lond) 1999; 521: 43–56.

43 Kim JA, Kang YS, Lee SH, Lee EH, Yoo BH, Lee YS. Glibenclamide induces apoptosis through inhibition of cystic fibrosis transmembrane conductance regulator (CFTR) Cl– channels and intracellular Ca2+ release in HepG2 human hepatoblastoma cells. Biochem Biophys Res Commun 1999; 261: 682–8.

44 Kim JA, Kang YS, Lee SH, Lee EH, Lee YS. Role of pertussis toxin-sensitive G-proteins in intracellular Ca2+ release and apoptosis induced by inhibiting cystic fibrosis transmembrane conductance regulator (CFTR) Cl– channels in HepG2 human hepatoblastoma cells. J Cell Biochem 2001; 81: 93–101.

45 Xu Y, Krause A, Hamal H, Harvey BG, Worgall TS, Worgall S. Proinflammatory phenotype and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNA. PLoS One 2010; 5: e11004.

46 Valverde MA, Vazquez E, Munoz FI, Nobles M, Delaney SJ, Wainwright BJ, et al. Murine CFTR channel and its role in regulatory volume decrease of small intestine crypts. Cell Physiol Biochem 2000; 10: 321–8.

47 L’hoste S, Chargui A, Belfodil R, Corcelle E, Duranton C, Rubera I, et al. CFTR mediates apoptotic volume decrease and cell death by controlling glutathione efflux and ROS production in cultured mice proximal tubules. Am J Physiol Renal Physiol 2010; 298: F435–53.

48 Barriere H, Poujeol C, Tauc M, Blasi JM, Couinillon L, Poujeol P. CFTR modulates programmed cell death by decreasing intracellular pH in Chinese hamster lung fibroblasts. Am J Physiol Cell Physiol 2001; 281: C810–24.

49 L’hoste S, Chargui A, Belfodil R, Duranton C, Rubera I, Mograbi B, et al. CFTR mediates cadmium-induced apoptosis through modulation of ROS level in mouse proximal tubule cells. Free Radic Biol Med 2009; 46: 1017–31.

50 Thevenod F. Multifaceted CFTR: novel role in ROS signaling and apoptotic cell death — a commentary on “CFTR mediates cadmium-induced apoptosis through modulation of ROS levels in mouse proximal tubule cells”. Free Radic Biol Med 2009; 46: 1014–6.

51 Yalcin E, Talim B, Ozcelik U, Dogru D, Cobanoglu N, Pekcan S, et al. Does defective apoptosis play a role in cystic fibrosis lung disease? Arch Med Res 2009; 40: 561–4.

52 Ruiz PE, Ponce ZA, Schanne OF. Early action potential shortening in hypoxic hearts: role of chloride current(s) mediated by catecholamine release. J Mol Cell Cardiol 1996; 28: 279–90.

53 Boujaoude LC, Bradshaw-Wilder C, Mao C, Cohn J, Ogretmen B, Hannun YA, et al. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. J Biol Chem 2001; 276: 35258–64.

54 Karliner JS. Lysophospholipids and the cardiovascular system. Biochim Biophys Acta 2002; 1582: 216–21.

55 Kunzelmann K. CFTR: interacting with everything? News Physiol Sci 2001; 16: 167–70.

56 Guggino WB, Stanton BA. New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol 2006; 7: 426–36.

57 Wang X, Venable J, LaPointe P, Hutt DM, Koulou AV, Coppinger J, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006; 127: 803–15.